ZAI LAB LIMITED SUCCESSFULLY LISTED ON HKEX
Latest Update:
28 th September, 2020

Shanghai, China, 28 September 2020 -- Zai Lab Limited (SEHK stock code: 9688, NASDAQ:ZLAB) announced that it is officially listed on the main board of the Stock Exchange of Hong Kong Limited (" SEHK "). The global offering of Zai Lab Limited totalled 10,564,050 shares (excluding the exercise of any over-allotment rights) and the net proceeds from the global offering are expected to be approximately HK $5.94 billion. As a result, Zai Lab Limited officially became the first biopharmaceutical company to be listed in Hong Kong.

In April 2018, the Hong Kong Stock Exchange began to implement new listing rules, adding a new chapter of biotechnology companies (Chapter 18A). The listing also marks Zai Lab Limited becoming the first nasdaq biopharmaceutical company to go public in Hong Kong under the new listing rules. Since its listing on NASDAQ in September 2017, Zai Lab Limited has been included in the NASDAQ Biotechnology Index (NBI), MSCI All China Index and many other important core component indexes.

Founded only six years ago, Zai Lab Limited has rapidly grown into an innovative biopharmaceutical company with global operations based in China. With the independent research and development and external cooperation, ding medicine again make up one of the most powerful innovation biotechnology companies in China late tumor of product line, with several global the first of the same kind or similar best drug, found in China and around the world, development, production and commercialization of innovative drugs, has become the industry one of the most trustworthy partner candidates.

Since its inception, the company has focused on oncology, anti-infection and autoimmune diseases, and is committed to bringing breakthrough innovative drugs to patients. The pipeline currently includes 16 potential best-in-class/first-in-class products and drug candidates. Ovarian cancer among them, the two product innovation medicine, joy and love, the world's first electric field treatment product shield has been listed in mainland China and Hong Kong and Macao regions, in addition, in the pipeline and nine product key or potential registered clinical research stage, two of them have been successfully submitted to China's state food and drug administration new drug applications (NDA) and qualification for priority review.

In the context of the COVID-19 pandemic, Zai Lab Limited continues to achieve leapfrog development this year. In May this year, Epudin was approved for the treatment of newly diagnosed and relapsed glioblastoma in mainland China, becoming the first innovative treatment approved for glioblastoma in China in 15 years. In September, the application for a complementary new drug for first-line maintenance therapy of ovarian cancer was approved, becoming the only PARP inhibitor approved for first-line maintenance therapy of ovarian cancer in the whole population. This year, the marketing applications of Omacycline toluenesulfate and repitinib were accepted and obtained priority review qualification, of which omacycline toluenesulfate is used for the treatment of cell acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infection (ABSSSI). Repatinib is used to treat adults with advanced gastrointestinal stromal tumor (GIST) who have been treated with three or more kinase inhibitors, including imatinib, and in July became the first drug specially approved to be removed from the Boao Lesheng Free Trade Port in Hainan. In addition, Zai Lab Limited and two global biopharmaceutical companies reached the authorization of the introduction of the best blockbuster products in the same category; In the first half of this year, 20 clinical study applications were approved and 25 clinical studies are planned or in progress. Two internally developed products have also entered global clinical phase and achieved the first patient administration.

Dr. Ying Du, founder, Chairman and CEO of Zai Lab Limited said, "We are very honored to receive the support and love of our investors. Today is an important milestone in the development of the company. The listing in Hong Kong is a high recognition of our business philosophy and achievements, and an important step in the vision of Zai Lab Limited to become a leading pharmaceutical company in the world. "Looking ahead, Zai Lab Limited will further expand its pipeline, seek to accelerate late stage clinical asset approval and commercialization, and advance the completion of other clinical or IND phase drug candidates to continue to deliver good returns to the company's shareholders and investors." In connection with the offering, Zai Lab Limited  will also grant the international underwriters an overallotment, which will allow the underwriters 30 days after September 22 to require the Company to issue up to 1,584,600 additional shares at the offering price. It is understood that the money raised will be related to its product line is mainly used for clinical development and internal research and development, to promote the ongoing and planned clinical trials, the commercialization of ascension, and love's shield included ability, and to explore new global licensing and cooperation opportunities, moreover also will be used for recruitment and training in the global high-end talent, etc., Support Zai Lab Limited pharmaceutical to discover, develop, produce and commercialize innovative drugs in China and around the world to further expand the company's scale and influence.

About Zai Lab Limited

Zai Lab Limited (NASDAQ: ZLAB) is an innovative biopharmaceutical company with operations in China and around the world, providing innovative medicines for patients with cancer, autoimmune and infectious diseases in China and around the world. Our experienced team has established strategic partnerships with leading biopharmaceutical companies around the world to create a portfolio of innovative drug candidates to meet the rapidly growing Chinese pharmaceutical market and unmet medical needs worldwide. Our vision is to become a comprehensive and innovative biopharmaceutical company that develops, manufactures and sells products developed independently and by our partners, and strives to promote the health and well-being of people all over the world. For more information about the company, please visit www.zailaborary.com 

Latest Update:
28 th September, 2020